Skip to main content
Premium Trial:

Request an Annual Quote

Genomatica Nabs UCSD, Penn State Bioengineering Licenses

NEW YORK, April 26-Privately held systems biology company Genomatica said on Wednesday that it has licensed bioengineering technology from the University of California, San Diego and the Pennsylvania State University.


These licenses, said the company, give it an edge in constraints-based modeling of metabolic and other regulatory processes.


Through the licenses, Genomatica gets access to the work of UCSD bioengineer Bernhard Paisson, and the regulatory network research of Penn State's Costas Maranas.


"These technologies will enable the integrated modeling of metabolism and regulation, positioning the company as a leader in the emerging field of in silico biology," said VP Christophe Schilling in a statement.


Constraints-based modeling, in Genomatica's work, seeks to integrate gene, protein, metabolite and phenotype information to create models of cellular activity.


Genomatica is based in San Diego, Calif.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.